A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
Latest Information Update: 08 Aug 2023
At a glance
- Drugs Suzetrigine (Primary) ; Hydrocodone/paracetamol
- Indications Acute pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 03 Aug 2023 According to a Vertex Pharmaceuticals media release, the company announced publication in the New England Journal of Medicine (NEJM) of preclinical data and the results from its Phase 2 proof-of-concept trials evaluating treatment with the selective, oral NaV1.8 inhibitor VX-548 for acute pain following abdominoplasty and bunionectomy surgeries.
- 03 Aug 2023 Results from two clinical trials (NCT04977336 and NCT05034952) assessing acute pain over a period of 48 hours after abdominoplasty or bunionectomy published in the New England Journal of Medicine
- 22 Jul 2022 According to a Vertex Pharmaceuticals media release, VX-548 was granted breakthrough Therapy Designation based on data from the phase 2 proof-of-concept studies.